 SAN DIEGO, June 1, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO today announced abstracts and presentations by its collaborators for the 2021 American Society of Clinical Oncology ASCO Annual Meeting, which will be held June 4-8, 2021. Janssen Research Development, LLC Janssen-sponsored study with therapeutics utilizing ENHANZE technology: Subcutaneous daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone VCd in patients with newly diagnosed light chain AL amyloidosis Oral abstract session: Updated results from the Phase 3 ANDROMEDA study of DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone D-VCd for the treatment of newly diagnosed AL amyloidosis Abstract 8003. 